GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Omeros Corporation
Omeros is a biopharmaceutical company with a long and complex history. Its stock price reflects both the revenue from its commercial drug and the numerous setbacks and delays in the development and approval of new drugs, leading to high volatility.
Share prices of companies in the market segment - Neuro
Omeros (OMER) is a biopharmaceutical company focused on the discovery and development of complement-targeted drugs for the treatment of rare kidney, blood, and CNS diseases. We classify it as a Neuroscience company. The chart below shows general trends in the orphan disease biotechnology sector.
Broad Market Index - GURU.Markets
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of complement-related diseases and central nervous system disorders. Its scientific developments make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Omeros compares to it.
Change in the price of a company, segment, and market as a whole per day
OMER - Daily change in the company's share price Omeros Corporation
The daily price change of Omeros, a biopharmaceutical company, reflects the risks associated with regulatory decisions. Change_co measures the high volatility associated with the approval of its drugs. This metric is important for analyzing binary events in biotech on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Omeros Corporation is a biotech company. This chart highlights the sector's extreme volatility. Comparison with OMER's performance, with its complex approval and development history, helps to appreciate its high risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Omeros is a biopharmaceutical company. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in this industry, allowing one to assess how Omeros's performance compares to overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Omeros Corporation
Omeros Corporation's year-over-year performance is a story of the search for a breakthrough in the treatment of complement-related diseases. Its 12-month market cap is crucially dependent on the results of clinical trials and FDA decisions regarding its lead drug. Success can open a multibillion-dollar market, but regulatory setbacks can cause serious damage.
Annual dynamics of market capitalization of the market segment - Neuro
Omeros Corporation is a biopharmaceutical company with an approved drug and an R&D pipeline. Its stock performance depends on both the commercial success of its product and the results of clinical trials. The chart shows how the market evaluates this complex, hybrid profile.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Omeros is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Omeros Corporation
Omeros, a biopharmaceutical company, depends on its product and R&D cycles. The monthly fluctuations on the chart reflect sales data for its approved drug and, more importantly, updates on interactions with the FDA regarding its other candidates.
Monthly dynamics of market capitalization of the market segment - Neuro
The biotech sector is full of dramatic stories, with company valuations often changing dramatically based on clinical and regulatory news. The dynamics of this segment, shown in the chart, reflect this volatility. It serves as the backdrop for complex stories like Omeros Corporation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Omeros Corporation is a biopharmaceutical company with a volatile history. Its shares react sharply to regulatory decisions and research data. Their performance is unpredictable and independent of overall market trends, which is typical for the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Omeros Corporation
Omeros, a biopharmaceutical company with a product on the market and several in development, faces a complex news cycle. Its weekly stock price reflects a combination of sales reports for its existing drug and speculative expectations surrounding the clinical trial results of its new candidates.
Weekly dynamics of market capitalization of the market segment - Neuro
Biopharmaceutical companies like Omeros, with a product on the market and a pipeline of developments, have a complex profile. The chart below shows the average performance for the sector. It allows you to compare how Omeros's combination of commercial successes and lab news impacts its performance relative to other companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Omeros is a biotech company with a single commercial product and a pipeline of developments. Its shares are highly sensitive to regulatory decisions and trial data. The chart will show how much its performance is determined by these unique factors, rather than by general market trends.
Market capitalization of the company, segment and market as a whole
OMER - Market capitalization of the company Omeros Corporation
Omeros Corporation's market capitalization chart is a story of high hopes and regulatory hurdles. Its dynamics reflect the company's years-long efforts to secure approval for its lead drug for a rare kidney disease. Its current value reflects investors' assessment of the likelihood of success after several FDA rejections.
OMER - Share of the company's market capitalization Omeros Corporation within the market segment - Neuro
Omeros Corporation is a biopharmaceutical company focused on treating complement-related diseases. In the neuroscience and immunology segments, its market capitalization reflects both revenue from its approved product and the potential of its research programs. The company's market capitalization is a complex balance between current commercial reality and future scientific expectations.
Market capitalization of the market segment - Neuro
This chart shows the overall value of the entire neuroscience and immunology pharmaceutical sector. For Omeros, a company with an approved product and an extensive research program, this line is a balance sheet. Its dynamics reflect how the market values both the company's current revenue and its risky but potentially breakthrough future projects.
Market capitalization of all companies included in a broad market index - GURU.Markets
Omeros Corporation is a biopharmaceutical company focused on treating diseases related to the complement system. Its market capitalization is determined by its scientific developments in the complex field of immunology. Its market share is determined by the share of drug discovery for rare diseases.
Book value capitalization of the company, segment and market as a whole
OMER - Book value capitalization of the company Omeros Corporation
Omeros Corporation is a biopharmaceutical company developing drugs for the treatment of inflammatory and neurological diseases. Its book value is a combination of its financial resources and research assets. It consists of cash for R&D and the cost of its developments. How has this capital changed? The chart below shows.
OMER - Share of the company's book capitalization Omeros Corporation within the market segment - Neuro
Omeros Corporation is a biotech company focused on the complement system. Its research and development requires a substantial infrastructure, including in-house laboratories and equipment for working with complex biological targets. The chart shows the company's share of the physical R&D infrastructure in this biopharma segment.
Market segment balance sheet capitalization - Neuro
Omeros, a biopharmaceutical company, has a moderately capital-intensive business. This requires ownership of R&D and control over the production of its drugs. The BCap_Seg chart for the biotech sector shows that commercial success requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Omeros's book value is derived from its commercial drug OMIDRIA, used in cataract surgery, and its immunology development portfolio. The company's assets are its intellectual property and commercial infrastructure. The chart below shows how this biotech business compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Omeros Corporation
Omeros's balance sheet consists of its R&D capital and commercial product. Its market value, which is below its book value, reflects investor concerns about the future sales of its only drug and the risks in its development pipeline.
Market to book capitalization ratio in a market segment - Neuro
Omeros is a biotech company. Its valuation on this chart is heavily dependent on regulatory decisions regarding its drugs and the success of clinical trials. This is a high-risk, high-reward scenario, typical of the biotech sector.
Market to book capitalization ratio for the market as a whole
Omeros is a biotech company with one approved drug and a pipeline of developments. Its market valuation is a complex combination of current sales and confidence in the future success of its R&D. This chart shows how the market weighs these two components: reality and hope.
Debts of the company, segment and market as a whole
OMER - Company debts Omeros Corporation
Omeros Corporation, a biopharmaceutical company, uses debt financing to support its commercial products and advance its clinical programs. This chart shows how the company balances current sales revenue with massive R&D expenditures as it strives to bring new drugs from its research pipeline to market.
Market segment debts - Neuro
Omeros Corporation is a commercial biotechnology company. Having a product on the market changes its financial position, but continuing R&D requires expenses. This chart shows how the company manages its debt, balancing revenue from current sales with funding its pipeline of future drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Omeros Corporation
Omeros is a biopharmaceutical company with one commercial product and several developments. This concentration carries risks. This chart shows its debt load. It is an indicator of its financial vulnerability: any problems with sales or research could seriously complicate debt servicing.
Market segment debt to market segment book capitalization - Neuro
Omeros Corporation is a biopharmaceutical company with a single commercial product and a pipeline of developments in inflammatory and neurological diseases. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how Omeros finances its expensive clinical research based on revenue from a single drug.
Debt to book value of all companies in the market
Omeros Corporation, a biopharmaceutical company focused on inflammatory and neurological diseases, has both a commercial product and clinical-stage development. This chart, showing the company's overall market leverage, helps assess its financial balance. It provides insight into how the company uses sales revenue to fund risky R&D and manage debt.
P/E of the company, segment and market as a whole
P/E - Omeros Corporation
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of complement-related diseases and inflammatory conditions. This chart shows how the market views its research and development efforts. These dynamics are heavily dependent on clinical trial successes and regulatory decisions.
P/E of the market segment - Neuro
Omeros is a biopharmaceutical company focused on the complement system. This chart shows the average valuation for the biotech sector. It helps understand how investors view its scientific developments and how its valuation is affected by clinical trial success and regulatory decisions.
P/E of the market as a whole
Omeros Corporation is a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting G protein receptors for the treatment of inflammatory and neurological diseases. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether OMER's valuation is based on the potential of its scientific platform or whether it moves in tandem with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Omeros Corporation
Omeros Corporation is a biotechnology company with a pipeline of developments in inflammatory and neurological diseases. Its future profitability depends on the success of clinical trials and approval of its drugs. This chart reflects the promise and risks associated with new drug development.
%20P%2FE%20Omeros%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Omeros-Corporation&v=1772676124417 "Chart of the company's future (projected) P/E Omeros Corporation")
Future (projected) P/E of the market segment - Neuro
Omeros Corporation is a biotechnology company developing drugs for the treatment of diseases related to the complement system, inflammation, and central nervous system disorders. The data here reflects the analysts' collective bet on the success of its clinical programs, especially after the failures of previous candidates.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772676124465 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Omeros Corporation is a biotech company with one approved product and a pipeline of developments in inflammatory diseases. This general expectations chart provides a backdrop against which investors can assess the risks associated with reliance on a single product and the uncertainty of clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772676124576 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Omeros Corporation
Omeros Corporation is a biopharmaceutical company with a commercial product and a pipeline of developments in inflammatory and neurological diseases. This chart illustrates the complex balance between revenue from current sales and future research costs. Profitability depends on success both in the marketplace and in the laboratory.
Profit of companies in the market segment - Neuro
Omeros Corporation is a biopharmaceutical company focused on treating complement-related diseases. Its financial history includes both a commercialized product and clinical-stage development. Its profitability is a combination of current sales and the potential of its research pipeline.
Overall market profit
Omeros Corporation is a biopharmaceutical company developing drugs for the treatment of inflammatory and neurological diseases. Its future depends on success in clinical trials and regulatory approval. The overall economic situation, reflected in this chart, influences the investment climate, which is critical to funding its expensive operations.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Omeros Corporation
Omeros Corporation is a biopharmaceutical company focused on complement-related diseases. This chart reflects analysts' speculative expectations. Future profits depend on the FDA's decision on their drug Narsoplimab and the success of their immunology research programs.
%20profit%20of%20the%20company%20Omeros%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Omeros-Corporation&v=1772676124825 "Graph of future (projected) profit of the company Omeros Corporation")
Future (predicted) profit of companies in the market segment - Neuro
Omeros Corporation is a biotech company focused on treating complement-related diseases. The profitability forecasts for the pharmaceutical industry, shown on this chart, provide a general overview. This chart helps assess how the company is overcoming regulatory challenges with its key drug and developing other programs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772676124892 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Omeros Corporation is a biopharmaceutical company focused on treating complement-related diseases. Its commercial success and research funding depend on regulatory approvals and overall market conditions. The positive economic environment, reflected in this chart, is improving the investment climate in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772676124928 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Omeros Corporation
Omeros Corporation is a biopharmaceutical company focused on treating diseases related to the complement system. Its revenue may be limited. This chart shows how investors view its scientific pipeline and the commercial potential of its lead drug candidate, which targets rare kidney diseases.
P/S market segment - Neuro
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of diseases associated with complement-mediated disorders and inflammation. This metric reflects the average revenue estimate in the sector and helps assess how investors perceive the company's scientific platform and clinical development.
P/S of the market as a whole
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of diseases related to the complement system, inflammation, and central nervous system dysfunction. This chart provides an opportunity to assess how the market perceives companies with established revenues, which serves as a backdrop for analyzing biotech companies with a broad but risky pipeline.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Omeros Corporation
Omeros Corporation is a biopharmaceutical company with a product for use in ophthalmic surgery and a pipeline of developments in inflammation and the central nervous system. This chart shows how investors estimate its future revenue. This estimate depends on sales of its existing product and the success of its clinical programs.
%20P%2FS%20Omeros%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Omeros-Corporation&v=1772676125164 "The graph of the company's future (projected) P/S Omeros Corporation")
Future (projected) P/S of the market segment - Neuro
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of complement-related diseases and central nervous system disorders. This chart compares market expectations for its future revenue with those of other neuroscience companies. The valuation reflects investor expectations for the approval and commercial success of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772676125182 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Omeros Corporation is a biotechnology company focused on developing drugs for the treatment of inflammatory and kidney diseases. Its future depends on regulatory approval of its key drug. This revenue guidance schedule is irrelevant for Omeros, whose value is determined by clinical and regulatory developments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772676125225 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Omeros Corporation
This chart shows the revenue of Omeros Corporation, a biopharmaceutical company. Its revenue is derived from sales of Omidria, but may also include payments from partners. Revenue dynamics can be volatile, depending on regulatory decisions, patent protection, and the success of clinical trials of other drugs in its portfolio.
Sales of companies in the market segment - Neuro
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of complement-related diseases, as well as inflammatory and oncological diseases. This chart shows revenue in the neuroscience sector. It reflects the complexity and high risks of biotech research, where companies like Omeros are working to develop breakthrough treatments.
Overall market sales
Omeros Corporation is a biotechnology company with a pipeline of developments in inflammation and central nervous system diseases. The company's success depends on its scientific achievements and regulatory approvals. The overall economic situation, shown in this chart, influences the overall investment climate in the biotechnology sector, which affects Omeros's ability to fund its research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Omeros Corporation
Omeros Corporation is a biopharmaceutical company with a commercial product and a development pipeline. This projected revenue chart reflects two aspects. Its dynamics are linked to sales expectations for its existing drug and, more importantly, to analysts' confidence in the potential of its research pipeline, particularly in the field of the complement system.
%20sales%20of%20the%20company%20Omeros%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Omeros-Corporation&v=1772676125398 "Schedule of future (projected) sales of the company Omeros Corporation")
Future (projected) sales of companies in the market segment - Neuro
Omeros Corporation is a biopharmaceutical company focused on developing treatments for complement-related diseases, as well as inflammatory and oncological diseases. This chart shows projected revenues for the entire neuroscience sector, reflecting the potential for drugs targeting fundamental biological pathways.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772676125434 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Omeros Corporation is a biotechnology company developing drugs for the treatment of inflammatory and neurological diseases. Its future depends on success in clinical trials and regulatory approval. The overall economic situation affects the availability of capital to finance long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772676125455 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Omeros Corporation
Omeros Corporation is a biopharmaceutical company with both a commercial product and a development pipeline. Its financial history is twofold. Its profitability chart shows how well revenues from sales of its existing drug can cover the significant R&D costs of new drugs, which are key to its future.
Market segment marginality - Neuro
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of complement-related diseases and other inflammatory disorders. This chart shows its financial performance. The company's profitability depends on the success of its commercial products and its ability to advance its extensive pipeline.
Market marginality as a whole
Omeros Corporation is a biopharmaceutical company with a pipeline of drugs at various stages of development. Its success depends on clinical trial results and regulatory decisions, not on the general economic cycles shown in this chart. Approval of a new drug can completely change the company's financial position.
Employees in the company, segment and market as a whole
Number of employees in the company Omeros Corporation
Omeros Corporation is a biopharmaceutical company with one approved product and a pipeline of developments. This graph shows the team facing regulatory challenges. The staffing dynamics may reflect both commercial efforts and restructuring related to delays in new drug approvals.
Share of the company's employees Omeros Corporation within the market segment - Neuro
Omeros Corporation is a biotechnology company focused on developing drugs for the treatment of inflammatory and neurological diseases. Its current focus is on scientific research conducted by a small team. This underscores its research-intensive nature: value is created in the laboratory, not through the scale of its workforce.
Number of employees in the market segment - Neuro
Omeros Corporation is a biotechnology company with one approved drug and a pipeline of developments in inflammatory diseases. This chart illustrates the challenges of commercialization. Employment dynamics can be highly dependent on drug reimbursement decisions by insurance companies and government agencies, which is a key factor in its success.
Number of employees in the market as a whole
Omeros Corporation is a biopharmaceutical company focused on treating inflammatory and neurological diseases. Its workforce dynamics are highly dependent on clinical trial results and regulatory decisions regarding its drugs. This overall workforce chart illustrates the risky and unpredictable nature of the biotech business, where a company's fate can hinge on a single decision.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Omeros Corporation (OMER)
Omeros Corporation is a biopharmaceutical company with a commercial ophthalmology product and a pipeline of immunology developments, specifically targeting the complement system. This chart shows how the market perceives the balance between current sales and the potential of future drugs. This figure can fluctuate significantly depending on R&D news.
%20of%20the%20company%20Omeros%20Corporation%20(OMER)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Omeros-Corporation-OMER&v=1772676126128 "Chart of market capitalization per employee (in thousands of dollars) of the company Omeros Corporation (OMER)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Omeros Corporation is a biopharmaceutical company focused on developing drugs for the treatment of inflammatory, complement-mediated, and oncological diseases. This metric reflects the market's assessment of their research portfolio. Deviation from the industry average may indicate investor confidence in the uniqueness of their developments and their commercial potential.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772676126157 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Omeros Corporation is a biopharmaceutical company focused on treating diseases related to the complement system. This metric reflects both the potential for scientific discovery and the risks of the biotech sector. The company's market capitalization is heavily dependent on clinical trial success and regulatory decisions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772676126272 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Omeros Corporation (OMER)
Omeros Corporation is a biotech company. They have one approved drug (Omidria), but their primary focus is on immunology R&D. This graph shows their financial position. It can be negative (R&D costs) or slightly positive, depending on the success of their commercial product.
%20Chart%20Omeros%20Corporation%20(OMER)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Omeros-Corporation-OMER&v=1772676126413 "Company Profit Per Employee (in thousands of dollars) Chart Omeros Corporation (OMER)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Omeros is a biotech company with one commercial product (Omidria, used in eye surgery) and a research pipeline. This metric is mixed: it reflects the profitability of their small commercial team and, at the same time, the significant investment of their R&D team, which is developing future products.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772676126448 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Omeros Corporation is a biotech company focused on treating complement-related diseases (part of the immune system). They are in the clinical and commercial stages. This chart shows the balance between whether the revenue from their commercial product (Omidria) offsets the enormous R&D costs associated with their other drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772676126466 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Omeros Corporation (OMER)
Omeros Corporation is a biopharmaceutical company focused on treating complement-related diseases and CNS disorders. This chart shows the company's progress toward commercialization. Revenue per employee growth will reflect success in securing approvals and launching its products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Omeros-Corporation-OMER&v=1772676126509 "Sales chart per company employee Omeros Corporation (OMER)")
Sales per employee in the market segment - Neuro
Omeros (OMER) is a biotech company with both a commercial product (Omiqria, used in eye surgery) and a development pipeline (in the field of complement systems). This graph shows the revenue generated by each employee. It reflects both the commercial success of their product and the productivity of their R&D division.
Sales per employee for the market as a whole
Omeros Corporation (OMER) is a biopharmaceutical company. Historically, they had a commercial product, Omidria (for cataract surgery), but now they focus on R&D in immunology (complement system). This metric is volatile, reflecting the transition from commercial revenue to an R&D-based model.
Short shares by company, segment and market as a whole
Shares shorted by company Omeros Corporation (OMER)
Omeros is a biotech company whose fate was tied to a single drug that ran into serious regulatory issues. This chart shows bearish bets. Bears are betting that the company will fail to secure FDA approval or that its remaining projects in development are worthless.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Omeros-Corporation-OMER&v=1772676126617 "Short Shares Chart for the Company Omeros Corporation (OMER)")
Shares shorted by market segment - Neuro
Omeros is a biotech company with one commercial product (for eye surgery) and a risky pipeline focused on the complement system. This chart shows short bets. The "short" here is a bet that their lead drug in development (narsoplimab) will not be approved by the FDA.
Shares shorted by the overall market
Omeros Corporation is a biotech focused on inflammatory and neurological diseases. The company has an approved product, but it still relies heavily on research. This chart of overall pessimism is important. Even with good news from OMER, if panic reigns in the market, investors may ignore the successes, preferring "safe" assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Omeros Corporation (OMER)
Omeros is a biotech company whose fate hinges on the FDA's approval of Narsoplimab. The company's stock lives in a binary "approval/rejection" mode. This chart measures the extremes of these expectations. It shows when the stock is "overbought" on hopes of approval or "oversold" to the bottom after another rejection.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Omeros-Corporation-OMER&v=1772676126727 "RSI 14 indicator chart for the company's stock Omeros Corporation (OMER)")
RSI 14 Market Segment - Neuro
Omeros Corporation is a biotech company specializing in the treatment of complement-related diseases (part of the immune system), with a focus on rare kidney diseases. This chart measures the overall momentum of the rare disease biotech sector. It helps separate OMER's volatility from the overall industry trend.
RSI 14 for the overall market
Omeros Corporation, a biotech company whose fate depends on this schedule, requires a constant influx of capital to fund expensive clinical trials. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like OMER are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OMER (Omeros Corporation)
Omeros Corporation is a biotech company whose key product, Narsoplimab, targets complement-related disorders. This chart shows the average 12-month price target of analysts. Their target price reflects a highly volatile view of the drug's FDA approval prospects after a long history of rejections.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OMER-Omeros-Corporation&v=1772676126951 "A chart showing analyst consensus forecasts for the expected stock price. OMER (Omeros Corporation)")
The difference between the consensus estimate and the actual stock price OMER (Omeros Corporation)
Omeros is a biopharmaceutical company with a complex portfolio. It has a commercial drug (Omidria) and is developing therapies for rare immune system diseases. This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in their R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OMER-Omeros-Corporation&v=1772676126985 "A chart showing the difference between the consensus forecast and the actual stock price. OMER (Omeros Corporation)")
Analyst consensus forecast for stock prices by market segment - Neuro
Omeros is a biotech company that, following the sale of its commercial product Omidria, is now fully focused on R&D (treatment of addictions and kidney diseases). This chart shows general expectations for the neuroscience sector, reflecting whether experts believe this risky R&D bet will be successful.
Analysts' consensus forecast for the overall market share price
Omeros Corporation is a biotech company focused on treating diseases related to the complement system (part of the immune system). This chart shows overall risk appetite. For Omeros, a company with a history of regulatory setbacks, overall market optimism is important for raising capital, but investors are much more focused on specific FDA news.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Omeros Corporation
Omeros is a biotech company whose fate is tied to the complex journey of their drug, Narsoplimab, which targets rare complement-related diseases. This chart is an assessment of their regulatory battle. Its dynamics reflect their long-standing and difficult dialogue with the FDA, as well as expectations for their R&D pipeline in neuroscience and immunology.
AKIMA Market Segment Index - Neuro
Omeros (OMER) is a biotech focused on inflammation; after the sale of Ophthotech, the company owns the approved drug Omidria (for cataract surgery) and is developing a portfolio of complement inhibitors. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this hybrid (product + R&D) model (OMER) differentiate it from the average pharma company?
The AKIM Index for the overall market
Omeros is a biopharmaceutical company focused on immunology and inflammatory diseases. It is known for its ophthalmology drug Omidria. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is addressing regulatory and commercial challenges, compares to overall economic trends.
